Advertisement

Topics

Lilly’s migraine drug lasmiditan succeeds in second phase 3 trial

02:27 EDT 7 Aug 2017 | Pharmaceutical Business Review

Eli Lilly's migraine drug lasmiditan has met its primary endpoint in a second phase 3 trial.

Original Article: Lilly’s migraine drug lasmiditan succeeds in second phase 3 trial

NEXT ARTICLE

More From BioPortfolio on "Lilly’s migraine drug lasmiditan succeeds in second phase 3 trial"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...